Royalty Pharma (RPRX) Projected to Post Quarterly Earnings on Tuesday

Royalty Pharma (NASDAQ:RPRX - Get Free Report) is projected to announce its earnings results before the market opens on Tuesday, February 11th. Analysts expect the company to announce earnings of $0.99 per share and revenue of $743.60 million for the quarter. Individual interested in listening to the company's earnings conference call can do so using this link.

Royalty Pharma Trading Up 1.1 %

RPRX traded up $0.33 during trading on Friday, hitting $31.73. 3,393,389 shares of the company's stock were exchanged, compared to its average volume of 4,115,620. The stock has a 50 day moving average price of $27.73 and a 200 day moving average price of $27.62. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.64. Royalty Pharma has a 1 year low of $24.05 and a 1 year high of $32.21. The firm has a market cap of $18.69 billion, a P/E ratio of 16.44 and a beta of 0.49.

Royalty Pharma Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 21st will be given a dividend of $0.22 per share. This is a boost from Royalty Pharma's previous quarterly dividend of $0.21. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.77%. The ex-dividend date of this dividend is Friday, February 21st. Royalty Pharma's payout ratio is presently 45.60%.

Wall Street Analysts Forecast Growth

RPRX has been the subject of several research analyst reports. StockNews.com raised shares of Royalty Pharma from a "hold" rating to a "buy" rating in a research report on Tuesday, November 5th. Citigroup reduced their price target on shares of Royalty Pharma from $60.00 to $40.00 and set a "buy" rating for the company in a research note on Friday, October 25th. Finally, TD Cowen upgraded shares of Royalty Pharma to a "strong-buy" rating in a report on Tuesday, December 24th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Royalty Pharma has an average rating of "Buy" and a consensus target price of $41.67.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.